Trial Profile

A phase 1 evaluating NKTR-255 in combination with CD19/22 CAR-T cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avipendekin pegol (Primary) ; CAR-T cell therapies (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Sponsors Nektar Therapeutics

Most Recent Events

17 Oct 2024 Results presented in the Nektar Therapeutics Media Release
08 Aug 2024 According to a Nektar Therapeutics media release, in July 2024, company's collaborators at Stanford published data in Blood, an open-access journal of the American Society of Hematology.
10 Apr 2024 Results (n=22) presented at the 115th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com